ATE409750T1 - Verbesserter adeno-assoziierter virus (aav)- vektor für gentherapie - Google Patents

Verbesserter adeno-assoziierter virus (aav)- vektor für gentherapie

Info

Publication number
ATE409750T1
ATE409750T1 AT04762994T AT04762994T ATE409750T1 AT E409750 T1 ATE409750 T1 AT E409750T1 AT 04762994 T AT04762994 T AT 04762994T AT 04762994 T AT04762994 T AT 04762994T AT E409750 T1 ATE409750 T1 AT E409750T1
Authority
AT
Austria
Prior art keywords
gene therapy
aav
vector
associated virus
adeno
Prior art date
Application number
AT04762994T
Other languages
English (en)
Inventor
Juergen Kleinschmidt
Oliver Mueller
Original Assignee
Mueller Dr Oliver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mueller Dr Oliver filed Critical Mueller Dr Oliver
Application granted granted Critical
Publication of ATE409750T1 publication Critical patent/ATE409750T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04762994T 2003-06-11 2004-06-09 Verbesserter adeno-assoziierter virus (aav)- vektor für gentherapie ATE409750T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03013169A EP1486567A1 (de) 2003-06-11 2003-06-11 Verbesserter Adeno-assoziierter Virus (AAV)-Vektor für Gentherapie

Publications (1)

Publication Number Publication Date
ATE409750T1 true ATE409750T1 (de) 2008-10-15

Family

ID=33185871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04762994T ATE409750T1 (de) 2003-06-11 2004-06-09 Verbesserter adeno-assoziierter virus (aav)- vektor für gentherapie

Country Status (5)

Country Link
US (1) US7629322B2 (de)
EP (2) EP1486567A1 (de)
AT (1) ATE409750T1 (de)
DE (1) DE602004016871D1 (de)
WO (1) WO2004111248A2 (de)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2376400A1 (en) 1999-06-08 2000-12-14 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
CA2520016A1 (en) 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene therapy of epithelial sodium channel associated disorders
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US8999678B2 (en) * 2005-04-07 2015-04-07 The Trustees Of The University Of Pennsylvania Method of increasing the function of an AAV vector
AU2007243184A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
US20090317417A1 (en) * 2006-04-28 2009-12-24 The Trustees Of The University Of Pennsylvania Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof
EP2018421B1 (de) 2006-04-28 2012-12-19 The Trustees of the University of Pennsylvania Skalierbares herstellungsverfahren für aav
EP2623605B1 (de) 2007-04-09 2018-11-28 University of Florida Research Foundation, Inc. rAAV-Vektorzusammensetzungen mit tyrosinmodifizierten Kapsidproteinen und Verwendungsverfahren dafür
US9725485B2 (en) 2012-05-15 2017-08-08 University Of Florida Research Foundation, Inc. AAV vectors with high transduction efficiency and uses thereof for gene therapy
US9611302B2 (en) 2007-04-09 2017-04-04 University Of Florida Research Foundation, Inc. High-transduction-efficiency RAAV vectors, compositions, and methods of use
DK2208737T3 (en) 2007-05-03 2017-09-18 Lysomab Gmbh Complement factor H-derived short-consensus repeat antibody constructs
CN102159713A (zh) 2008-05-20 2011-08-17 Eos神经科学公司 用于递送光敏蛋白的载体和使用方法
EP2687609B1 (de) 2008-11-10 2017-01-04 The United States of America, as represented by The Secretary, Department of Health and Human Services Behandlung von soliden Tumoren
EP2396343B1 (de) * 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
JP6042825B2 (ja) * 2011-02-10 2016-12-14 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
DK4005603T3 (da) 2011-04-22 2024-11-25 Univ California Adeno-associerede virus-virioner med variant kapsid og fremgangsmåder til anvendelse heraf
US9987354B2 (en) 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
RU2683497C2 (ru) * 2012-04-18 2019-03-28 Дзе Чилдрен'З Хоспитал Оф Филадельфия Композиция и способы высокоэффективного переноса генов с помощью вариантов капсида aav
WO2013159036A1 (en) * 2012-04-19 2013-10-24 Oregon Health & Science University Adeno associated virus plasmids and vectors
US12358954B2 (en) 2012-05-15 2025-07-15 University Of Florida Research Foundation, Incorporated Capsid-modified rAAV vector compositions and methods therefor
US10294281B2 (en) 2012-05-15 2019-05-21 University Of Florida Research Foundation, Incorporated High-transduction-efficiency rAAV vectors, compositions, and methods of use
JP6199965B2 (ja) 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｒｐｇｒｘ連鎖性網膜変性のａａｖ媒介型遺伝子治療
US9567376B2 (en) 2013-02-08 2017-02-14 The Trustees Of The University Of Pennsylvania Enhanced AAV-mediated gene transfer for retinal therapies
CN110251675A (zh) 2013-05-03 2019-09-20 西莱克塔生物科技公司 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体
EP2999791B1 (de) * 2013-05-21 2018-12-05 University of Florida Research Foundation, Inc. Kapsidmodifizierte, raav3-vektorzusammensetzungen und verfahren zur verwendung in der gentherapie von leberkrebs bei menschen
CA2907799A1 (en) 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
US10308957B2 (en) 2014-03-04 2019-06-04 University Of Florida Research Foundation, Inc. rAAV vectors and methods for transduction of photoreceptors and RPE cells
ES3042252T3 (en) 2014-03-17 2025-11-19 Adverum Biotechnologies Inc Compositions and methods for enhanced gene expression in cone cells
EP3628334B1 (de) 2014-03-21 2023-06-28 Genzyme Corporation Gentherapie für retinitis pigmentosa
WO2015168666A2 (en) 2014-05-02 2015-11-05 Genzyme Corporation Aav vectors for retinal and cns gene therapy
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
WO2016037161A2 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses
CN112553229A (zh) 2014-11-05 2021-03-26 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
MX2017006217A (es) 2014-11-14 2018-05-02 Voyager Therapeutics Inc Polinucleotidos moduladores.
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
EP4636401A2 (de) 2014-12-19 2025-10-22 The Broad Institute, Inc. Verfahren zur profilierung des t-zell-rezeptor-repertoirs
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US20180030096A1 (en) 2015-02-03 2018-02-01 University Of Florida Research Foundation, Inc. Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
WO2016133917A1 (en) 2015-02-16 2016-08-25 University Of Florida Research Foundation Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes
CN114480502A (zh) 2015-03-02 2022-05-13 阿德夫拉姆生物技术股份有限公司 用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
WO2016154344A1 (en) 2015-03-24 2016-09-29 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
WO2016186772A2 (en) 2015-05-16 2016-11-24 Genzyme Corporation Gene editing of deep intronic mutations
WO2017062750A1 (en) 2015-10-09 2017-04-13 The Trustees Of The University Of Pennsylvania Compositions and methods useful in treating stargardt's disease and other ocular disorders
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
EP3387118B1 (de) 2015-12-11 2022-04-06 The Trustees Of The University Of Pennsylvania Skalierbares reinigungsverfahren für aavrh10
US11098286B2 (en) 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
JP7057281B2 (ja) 2015-12-14 2022-04-19 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 眼疾患のための遺伝子療法
WO2017139381A1 (en) 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
IL322737A (en) 2016-03-07 2025-10-01 Univ Iowa Res Found AAV-mediated expression using a synthetic promoter and enhancer
AU2017248656B2 (en) 2016-04-15 2023-07-27 The Trustees Of The University Of Pennsylvania Novel AAV8 mutant capsids and compositions containing same
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
CN116333057A (zh) 2016-05-13 2023-06-27 4D分子治疗有限公司 腺相关病毒变体衣壳和其使用方法
BR112018073472A2 (pt) 2016-05-18 2019-08-27 Voyager Therapeutics, Inc. composições e métodos de tratamento da doença de huntington
AU2017267665C1 (en) 2016-05-18 2023-10-05 Voyager Therapeutics, Inc. Modulatory polynucleotides
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
KR102526506B1 (ko) 2016-07-08 2023-05-03 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
CA3029833A1 (en) 2016-07-29 2018-02-01 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US11698377B2 (en) 2016-08-15 2023-07-11 Genzyme Corporation Methods for detecting AAV
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
MX2019008143A (es) 2017-01-07 2020-01-13 Selecta Biosciences Inc Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos.
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
JP7237843B2 (ja) 2017-02-21 2023-03-13 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 修飾されたａａｖキャプシドタンパク質およびその使用
CN119752819A (zh) 2017-03-01 2025-04-04 宾夕法尼亚州立大学托管会 用于眼部病症的基因疗法
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
US11879133B2 (en) 2017-04-24 2024-01-23 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
IL316926A (en) 2017-05-11 2025-01-01 Univ Pennsylvania Gene therapy for neuronal ceroid lipofuscinosis
CA3098592A1 (en) 2017-05-31 2018-12-06 The Trustees Of The University Of Pennsylvania Gene therapy for treating peroxisomal disorders
WO2018232149A1 (en) 2017-06-14 2018-12-20 The Trustees Of The University Of Pennsylvania Gene therapy for ocular disorders
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
BR112019019015A2 (pt) 2017-06-30 2020-04-14 Univ California vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso
CN111132626B (zh) 2017-07-17 2024-01-30 沃雅戈治疗公司 轨迹阵列引导系统
WO2019028306A2 (en) 2017-08-03 2019-02-07 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
EP3676373A4 (de) 2017-08-28 2021-06-09 The Regents of The University of California Capsid-varianten von adeno-assoziierten viren und verfahren zur verwendung davon
EP3687561A4 (de) 2017-09-01 2021-06-09 The Australian National University Immunregulatorische moleküle und deren verwendung
BR112020005436B1 (pt) 2017-09-20 2022-08-02 4D Molecular Therapeutics Inc Proteína do capsídeo de variante do vírus adenoassociado, virion do aav recombinante (raav) infeccioso, composições, composições farmacêuticas e usos de virion de raav ou de composições farmacêuticas
EP3461836A1 (de) * 2017-09-28 2019-04-03 Universität zu Köln Mutierte kapsid proteine von adeno-assoziierten viren zur chemischen kopplung von liganden, nanopartikeln oder medikamenten über thioetherbindung und methode zu deren herstellung
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
FI3717636T3 (fi) 2017-11-27 2023-06-01 4D Molecular Therapeutics Inc Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
CN111601620A (zh) 2018-01-17 2020-08-28 阿瑞纳斯治疗公司 用于21-羟化酶缺乏症的腺相关病毒基因疗法
US12178908B2 (en) 2018-02-26 2024-12-31 AnTolRx, Inc. Tolerogenic liposomes and methods of use thereof
WO2019173334A1 (en) * 2018-03-05 2019-09-12 The Schepens Eye Research Institute, Inc. Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration
AU2019270900B2 (en) 2018-05-15 2026-03-12 President And Fellows Of Harvard College Viral vectors exhibiting improved gene delivery properties
AU2019268330A1 (en) 2018-05-15 2020-11-26 Voyager Therapeutics, Inc. Compositions and methods for the treatment of Parkinson's disease
MX2021000638A (es) 2018-07-16 2021-06-23 Selecta Biosciences Inc Métodos y composiciones de construcciones y vectores de acidemia metilmalónica.
CA3106639A1 (en) 2018-07-16 2020-01-23 Selecta Biosciences, Inc. Methods and compositions of otc constructs and vectors
EP3856762A1 (de) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin-expressionskonstrukte mit gentechnisch veränderten promotoren und verfahren zu deren verwendung
US20220154211A1 (en) 2019-02-25 2022-05-19 Novartis Ag Compositions and methods to treat bietti crystalline dystrophy
BR112021016501A2 (pt) 2019-02-25 2021-10-26 Novartis Ag Composições e métodos para tratar distrofia cristalina de bietti
JP7637060B2 (ja) 2019-03-04 2025-02-27 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａｋｔ経路を標的とする神経保護遺伝子療法
WO2020223205A1 (en) 2019-04-28 2020-11-05 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
US12516351B2 (en) 2019-04-29 2026-01-06 The Trustees Of The University Of Pennsylvania AAV capsids and compositions containing same
EP3736330A1 (de) 2019-05-08 2020-11-11 European Molecular Biology Laboratory Partikel mit modifiziertem adeno-assoziiertem virus (aav) zur gentherapie
WO2020243261A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
US20220372512A1 (en) * 2019-07-04 2022-11-24 Children's Medical Research Institute Methods and aav vectors for in vivo transduction
GB2700048B (en) 2019-09-18 2026-03-04 Aldevron Llc synthetic dna vectors and method of use
WO2021076600A1 (en) 2019-10-14 2021-04-22 Duke University Compositions comprising novel prokaryotic sodium channels and associated methods
EP4133093A4 (de) * 2020-04-08 2024-05-22 President And Fellows Of Harvard College Tgfbeta-therapie für augen- und neurodegenerative erkrankungen
CA3188956A1 (en) * 2020-08-14 2022-02-17 James M. Wilson Novel aav capsids and compositions containing same
JP2023540756A (ja) * 2020-09-04 2023-09-26 オハイオ・ステイト・イノベーション・ファウンデーション 向上した形質導入効率及び脳内における広範な分布を有する組換えアデノ随伴ウイルスベクターの新規の操作されたキャプシド血清型
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
JP2023545731A (ja) 2020-10-07 2023-10-31 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 肢帯型２ｉ（ｌｇｍｄ２ｉ）を含むジストログリカノパチー障害を処置するためのフクチン関連タンパク質（ｆｋｒｐ）の治療的アデノ随伴ウイルス送達
CN117042787A (zh) 2020-10-29 2023-11-10 宾夕法尼亚州大学信托人 Aav衣壳和含有aav衣壳的组合物
WO2022150335A1 (en) 2021-01-05 2022-07-14 Selecta Biosciences, Inc. Viral vector dosing protocols
EP4284335A1 (de) 2021-02-01 2023-12-06 RegenxBio Inc. Gentherapie für neuronale ceroid-lipofuscinosen
CA3212876A1 (en) 2021-03-19 2022-09-22 Adrenas Therapeutics, Inc. Gene therapies for 21-hydroxylase deficiency
WO2022232267A1 (en) 2021-04-27 2022-11-03 The Trustees Of The University Of Pennsylvania Porcine-derived adeno-associated virus capsids and uses thereof
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
JP2024539012A (ja) 2021-10-12 2024-10-28 ブリッジバイオ ジーン セラピー エルエルシー 白質ジストロフィーを治療するための方法及び組成物
EP4415760A1 (de) 2021-10-12 2024-08-21 Cartesian Therapeutics, Inc. Dosierungsprotokolle für virale vektoren
EP4429662A1 (de) 2021-11-14 2024-09-18 Cartesian Therapeutics, Inc. Mehrfachdosierung mit viralen vektoren
WO2023156530A1 (en) 2022-02-17 2023-08-24 Lysogene Gene therapy for neurodegenerative diseases
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
US20260021205A1 (en) 2022-07-15 2026-01-22 The Trustees Of The University Of Pennsylvania Recombinant aav having aav clade d and clade e capsids and compositions containing same
WO2024036324A1 (en) 2022-08-11 2024-02-15 Selecta Biosciences, Inc. Compositions and methods related to immunoglobulin proteases and fusions thereof
CN117402222B (zh) * 2023-11-17 2024-03-29 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162796A (en) * 1995-09-27 2000-12-19 The Rockefeller University Method for transferring genes to the heart using AAV vectors
WO2002053703A2 (en) * 2001-01-05 2002-07-11 Children's Hospital, Inc. Aav2 vectors and methods
EP1456383B1 (de) * 2001-12-21 2014-03-12 Medigene AG Zur identifizierung viraler klone mit gewünschtem zelltropismus geeignete bibliothek modifizierter strukturgene oder capsidmodifizierter partikel
EP1496944B1 (de) 2002-05-01 2008-08-20 University of Florida Research Foundation, Inc. Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine

Also Published As

Publication number Publication date
EP1486567A1 (de) 2004-12-15
EP1664314A2 (de) 2006-06-07
DE602004016871D1 (de) 2008-11-13
WO2004111248A2 (en) 2004-12-23
EP1664314B1 (de) 2008-10-01
US7629322B2 (en) 2009-12-08
US20070036757A1 (en) 2007-02-15
WO2004111248A3 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
ATE409750T1 (de) Verbesserter adeno-assoziierter virus (aav)- vektor für gentherapie
CY1124371T1 (el) Ιοσωματια aav me μειωμενη ανοσοαντιδραστικοτητα και χρησεις αυτων
CY2021024I1 (el) Ομαδες, αλληλουχιες, φορεις αδενο-σχετιζομενου ιου (aav) που περιεχουν αυτον, και οι χρησεις τους
WO2004027019A3 (en) Improved raav expression systems for genetic modification of specific capsid proteins
IL221602A (en) Virus sequences belonging to the rh10 adenoid type and recombinant viruses containing them
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
WO2002053703A3 (en) Aav2 vectors and methods
WO2003006616A3 (en) Pseudotyped adeno-associated viruses and uses thereof
WO2007120542A3 (en) Aav capsid library and aav capsid proteins
IT1297074B1 (it) Forme ormone-dipendenti delle proteine rep del virus adeno-associato (aav-2), sequenze di dna codificanti per esse, vettori che le
IL199127A (en) Promoters for expression in modified vaccinia virus ankara (mva) and vectors comprising said promoters
EP1546343A4 (de) Produktion von rekombinantem aav mit hohem titer
AU2002325683A1 (en) Recombinant vector derived from adeno-associated virus for gene therapy
WO2005049850A3 (en) Compositions and methods for systemic nucleic acid sequence delivery
ATE435293T1 (de) Invertierte terminale repeats von aav, die für die transkription aktiviert sind, zur verwendung in rekombinanten aav-vektoren
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
WO2023194796A3 (en) Recombinant aav capsid proteins
WO2002002148A3 (en) Dual recombinant gene therapy compositions and methods of use
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
ATE442441T1 (de) Virale expressionsvektoren für pflanzen
DE60038955D1 (de) AN DER OBERFLÄCHE VON KARZINOMZELLEN LOKALISIERTES COLLIGIN/HsP47
WO2023242633A3 (en) Recombinant aav capsid proteins
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
WO2024064782A3 (en) Adeno-associated virus capsids

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties